Aurinia Pharmaceuticals Inc.AUPHNASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average, modest growth trend.
Left:
||||
Year-over-year operating income growth rate
Latest
48.11%
↑ 26% above average
Average (39q)
38.33%
Historical baseline
Range
High:1408.99%
Low:-527.71%
CAGR
+3.2%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 48.11% |
| Q2 2025 | -8.07% |
| Q1 2025 | 1408.99% |
| Q4 2024 | -114.21% |
| Q3 2024 | 876.47% |
| Q2 2024 | 85.85% |
| Q1 2024 | 63.96% |
| Q4 2023 | -82.46% |
| Q3 2023 | -0.58% |
| Q2 2023 | 45.34% |
| Q1 2023 | -5.28% |
| Q4 2022 | -195.82% |
| Q3 2022 | 73.61% |
| Q2 2022 | 5.00% |
| Q1 2022 | -15.83% |
| Q4 2021 | 35.05% |
| Q3 2021 | -6.83% |
| Q2 2021 | 6.74% |
| Q1 2021 | -527.71% |
| Q4 2020 | 80.97% |
| Q3 2020 | -57.52% |
| Q2 2020 | 0.73% |
| Q1 2020 | -29.47% |
| Q4 2019 | 12.96% |
| Q3 2019 | -45.93% |
| Q2 2019 | -10.54% |
| Q1 2019 | -1.51% |
| Q4 2018 | -3.93% |
| Q3 2018 | 1.62% |
| Q2 2018 | -9.91% |
| Q1 2018 | -7.48% |
| Q4 2017 | 11.97% |
| Q3 2017 | -37.23% |
| Q2 2017 | 9.35% |
| Q1 2017 | -38.13% |
| Q4 2016 | -48.89% |
| Q3 2016 | -18.41% |
| Q2 2016 | 6.09% |
| Q1 2016 | 12.26% |
| Q4 2015 | 14.06% |